GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Irinotecan hydrochloride overview

Irinotecan Hydrochloride (Yueyouli) is a semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree camptotheca acuminata. It is formulated as solution for intravenous route of administration. Irinotecan hydrochloride is indicated for the treatment of patients with metastatic pancreatic cancer after disease progression following gemcitabine-based therapy.

Irinotecan hydrochloride liposome is under development for the treatment of  metastatic pancreatic cancer, pancreatic ductal adenocarcinoma, metastatic colorectal cancer, esophageal cancer, esophageal squamous cell carcinoma and small-cell lung cancer. It acts by targeting DNA topoisomerase I. It is administered through intravenous route.

It was also under development for solid tumors.

Jiangsu Hengrui Medicine overview

Jiangsu Hengrui Medicine (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture, and distribution of novel pharmaceutical products. Its product portfolio includes anti-tumor drugs, surgical drugs, contrast agents, angiomyocardiac drugs, and antibiotics. The company is also developing pipeline products for the treatment of cancer, Crohn’s disease, anemia, diabetes, atopic dermatitis, chronic bone disease, blood pressure, and hypercholesterolemia. Jiangsu Hengrui has R&D facilities in China, the US, and Japan. The company offers products through its sales and distribution network in China, the US, Japan, Germany Switzerland and Australia. Jiangsu Hengrui is headquartered in Lianyungang, Jiangsu Province, China.

For a complete picture of Irinotecan hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.